May 11, 2022 Bio/Pharma/CRO [Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer Read more
May 10, 2022 Uncategorized Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028 Read more
April 29, 2022 Licensing, IP, and Legal Product Launch New three-year data for Roche’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) Read more
April 25, 2022 PR/Corporate [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022 Read more
April 22, 2022 Uncategorized CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer Read more
April 22, 2022 Uncategorized CHMP recommends EU conditional approval of Roche’s potential first-in-class bispecific antibody mosunetuzumab for people with relapsed or refractory follicular lymphoma Read more
April 4, 2022 Acad, Gov/Utilities Clinical Research/Diagn. Microscopy U.S. FDA grants priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults Read more
April 4, 2022 Licensing, IP, and Legal Product Launch New data for Roche’s OCREVUS (ocrelizumab) show benefit in disability progression and cognitive decline in both secondary progressive and primary progressive multiple sclerosis Read more
March 30, 2022 Bio/Pharma/CRO Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer Read more
March 25, 2022 Uncategorized CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma Read more
